PRL-8-53

PRL-8-53 (methyl 3-[2-[benzyl(methyl)amino]ethyl]benzoate hydrochloride) is a synthetic substituted phenethylamine and benzoate ester first synthesized by Nikolaus R. Hansl at Creighton University in the early 1970s as part of a systematic exploration of amino ethyl meta-benzoic acid esters for spasmolytic and psychotropic activity. The compound is classified as a hypermnesic agent on the basis of a single published double-blind, placebo-controlled human study (Hansl and Mead, 1978) in which a 5 mg oral dose produced statistically significant improvement in the retention of serially presented verbal material in 47 healthy volunteers, with the most pronounced effects observed in subjects over 30 years of age who had below-average baseline recall performance. The magnitude of the retention enhancement was substantial: subjects in the over-30 subgroup demonstrated approximately 108 percent improvement in 24-hour recall and 152 percent improvement in one-week recall relative to their placebo performance, with most P values better than 0.01 and some better than 0.001. The compound did not significantly alter visual reaction time or motor control at the studied dose, suggesting a selective cognitive action rather than generalized central nervous system stimulation.

The molecular pharmacology of PRL-8-53 remains incompletely characterized. Preclinical evidence from Hansl's laboratory and from the patent literature (US 3,870,715; granted March 11, 1975) indicates that the compound potentiates dopaminergic neurotransmission, partially inhibits serotonergic activity, and displays possible cholinergic properties. In animal models, PRL-8-53 reverses reserpine-induced catatonia and ptosis, improves avoidance learning in conditioned response paradigms, and exhibits spasmolytic activity against acetylcholine-, barium chloride-, and histamine-induced smooth muscle contraction. The compound does not exhibit stimulant properties at doses up to 200 mg/kg in rodents and does not potentiate the locomotor effects of dextroamphetamine at 20 mg/kg. The oral median lethal dose in mice is approximately 860 mg/kg, conferring a therapeutic index of approximately 170 relative to the projected human-equivalent dose, and chronic toxicology studies in rats, dogs, and monkeys through two offspring generations revealed no evidence of organ pathology or teratogenicity.

Despite these promising early findings, no additional controlled human studies have been published since the 1978 report. The compound's development was interrupted by Hansl's retirement from Creighton University and a 1985 institutional dispute that resulted in the loss of stored experimental materials. The patent expired in approximately 1992, placing the compound in the public domain. Formal pharmacokinetic characterization in humans has not been published; the plasma elimination half-life is estimated at 2 to 4 hours on the basis of the compound's structural properties and the time course of cognitive effects observed in the Hansl study. The metabolic pathways, routes of elimination, plasma protein binding, and blood-brain barrier penetration characteristics remain uncharacterized. PRL-8-53 is not approved by any regulatory authority for any indication. It is available as a research-grade preparation from multiple chemical suppliers at greater than 98 percent purity; investigators should obtain independent analytical confirmation of identity and purity on every lot. This monograph reviews the chemistry, synthesis, and structural classification of PRL-8-53; the available preclinical pharmacology; the single published human study in detail; the limited pharmacokinetic information; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal; and a structured comparative assessment of five nootropic memory-enhancing compounds against PRL-8-53 on five competency standards.